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Introduction
Myotonic dystrophy (MD) is a multi-system disorder,
the most well known symptoms being muscle weak-
ness and myotonia. Distressing daytime sleepiness
and diminished spontaneous activity, often referred
to as inertia, reduced initiative, inactivity or apathy,
are frequently reported. These latter symptoms often
seem to cause more hindrance in daily life, both to
patients and their spouses, than muscle weakness it-
self. Hypersomnia can even be present when there is
virtually no weakness [1]. Recent reports [2, 3, 4] have
demonstrated that modaﬁnil has a beneﬁcial effect on
daytime sleepiness in MD. Although the relationship
between excessive sleepiness and the lack of sponta-
neous activity is not clear, it seemed reasonable to
suppose that increasing vigilance might result in an
increase in spontaneous activity. The present study
intended to answer the following questions: ﬁrstly, do
patients with MD undertake more activities when
using modaﬁnil; secondly, does any such improve-
ment relate to a change in somnolence or to another
disease characteristic?
Patients and methods
Thirteen outpatients (5 males) participated in a ran-
domized double-blind crossover placebo controlled
study. Their mean age was 43.5 years (SD: 13.9 years).
Age of onset of symptoms was before 12 years of age
in 3 patients; all three lived independently at the time
of study, although they needed professional social
support with respect to their household or daily
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j Abstract We performed a
double-blind placebo-controlled
crossover study in 13 patients with
myotonic dystrophy to address the
question whether modaﬁnil,
known to improve hypersomno-
lence in myotonic dystrophy, may
improve levels of activity as well.
We used the Epworth Sleepiness
Scale as a measure of hypersom-
nolence and a structured interview
of the patient and the partner or
housemate as a measure of activ-
ity. We additionally used a
restricted form of the RAND-36 to
relate a possible improvement of
activity to perceived general
health. We conﬁrmed earlier
positive ﬁndings of modaﬁnil
regarding reduced somnolence
(p = 0.015), but no signiﬁcant
effects were seen regarding activity
levels (p = 0.2 for patients’ self-
reports and 0.5 for partners’
reports).
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E-Mail: axelwintzen@hetnet.nlactivities. Three patients were employed in highly
responsible jobs. The remaining patients had been
considered unﬁt for normal paid employment for
reasons related to their disorder. They were mainly
involved in housekeeping. With the exception of two
elderly men with considerable weakness of the legs,
weakness had little impact on activities of daily living
(ADL) functions. Even these two men were ambulant,
although they used a wheelchair regularly. Twelve
patients had a partner or housemate.
Medication was given during two periods of
14 days, separated by a one-week washout period.
The study was preceded by a two-week period free of
all drugs with an exception being made for contra-
ception. Patients were randomized for either placebo
ﬁrst or modaﬁnil ﬁrst. The modaﬁnil dose was 200 mg
per day for the ﬁrst week. The patients were in-
structed to double the dose during the second week of
each period if they perceived an insufﬁcient effect.
The main outcome measure was an increase in
spontaneous activity, assessed using a novel struc-
tured interview of both the patient and the partner or
housemate, if present. These interviews took place at
home after the ﬁrst period, and by telephone after the
second one. After the ﬁrst medication period the pa-
tient and the partner/housemate were asked to com-
pare the level of activity with that of the preceding two
(-baseline-) weeks. After the second medication per-
iod they were asked to compare that period with the
baseline weeks.
The following issues were addressed, and scores
attributed:
– have you, during the past two weeks, been more
active than during the baseline period?
– no (0 points)
– to some degree (1 point)
– deﬁnitely (2 points)
– can you give one (1 point), two (2 points) or three
(3 points) substantial and observable examples of
activities/speciﬁc actions you undertook that you
would otherwise not have done?
The range of the score was therefore zero to ﬁve
points. The partner was asked the same questions
with respect to the patient. During the interview pa-
tients and partners were asked whether they had
guessed which medication, modaﬁnil or placebo, the
patient had used in the past period. If so, they were
asked what made them believe so. The answers were
not used in the assessment of medication effects, but
served to estimate possible unblinding. The RAND-36
questionnaire was used to measure possible changes
in subjective general health [5]. This was ﬁlled in
before the start and after the end of each medication
period. The questionnaire was restricted to issues
considered relevant to the study: General Health, Role
Limitations by emotional and physical problem,
Social Functioning, Vitality, and Mental Health. The
Epworth Sleepiness Scale (ESS, [6] was used to assess
possible changes in hypersomnolence.
After completion of the trial the remaining cap-
sules in the medication boxes were counted to
assess compliance. The institutional Committee of
Medical Ethics had approved the study. Patients
gave written informed consent after study infor-
mation was provided orally and in writing at the
patients’ home.
Results
All patients completed the trial. Medication compli-
ance was good: only three patients had omitted one
dose each. The only reported side effect was slight
headache in one patient using modaﬁnil. Ten pa-
tients doubled the dose of both modaﬁnil and pla-
cebo after the ﬁrst week, meaning that results largely
concern a daily dose of 400 mg modaﬁnil. More
often than not both patients (67%) and their part-
ners/housemates (77%) correctly guessed when they
had been taking either modaﬁnil or Placebo, usually
on the basis of a  decreased sleepiness’ and/or  in-
creased activity’.
The structured interview regarding activity and
actions did not show signiﬁcant differences between
modaﬁnil and placebo (p = 0.2 for patients and
p = 0.5 for partners/housemates).
The RAND-36 questionnaires revealed a poor
perception of general health for the whole group with
a mean value of 29 points out of 100 (range 0–50) on
the General Health rating.
The ratings were virtually identical for each patient
over the four assessments (p = 1,Wilcoxon test). The
perception of Role Limitations varied widely: mean 66
out of 100 (range 0–100). A medication related change
was not observed (p = 0.7, Wilcoxon test). This also
held for the perception of Social Functioning
(p = 0.6), Vitality (p = 0.2) and Mental Health
(p = 0.5). The ESS revealed a signiﬁcant improvement
with modaﬁnil, in that the mean score decreased from
10.5 (range: 3–18) to 6.8 points (range: 1–15); for
placebo the corresponding values were 10.5 (range: 3–
18) and 10.7 (range: 2–17) points (p = 0.015, Wilco-
xon test). There was no suggestion of a difference in
outcome between patients with high and those with
low scores. There was no signiﬁcant relationship be-
tween the increase in activity/actions as perceived by
the patient/ partner and indicated by the structured
interview, and changes in perceived hypersomnolence
as measured by the ESS (p = 0.38, Spearman’s test).
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The present study conﬁrmed the beneﬁcial effect of
modaﬁnil on excessive sleepiness in MD, but did not
detect a concomitant effect on spontaneous activity as
measured by a structured interview of the patients
and their partners. This interview, not formally vali-
dated, was designed to reﬂect a clinically relevant and
observable increase in daily activity by asking for
speciﬁc actions. Examples might be that patients went
to the theatre after a busy day, when they would
otherwise have postponed such a visit, or cleaning up
the shed. By asking for speciﬁc actions we hoped to
distinguish actions from the mere feeling of being
active or the intention to become so.
The study was small, leaving open the possibility
that minor changes have been missed. The study was
also focused on short-term effects and thus it is not
able to detect changes of behaviour that take more
time to become manifest, but we believe that a fort-
night is long enough to detect relevant improvements
in activity as deﬁned above. A further consideration is
the unblinding we have observed, which was most
probably due to a correct perception of an effect on
somnolence. This might have confounding effects on
the interpretation of intended double-blind studies of
modaﬁnil on symptoms other than hypersomnolence.
In the present study this does not seem to have
happened, as the effect on hypersomnolence was
neither related to perceived improved activity, nor to
perceived aspects of general health. That many pa-
tients and partners reported more activity in addition
to less sleepiness when asked why they thought that
modaﬁnil or placebo had been used, might be the
result of the expectations implied in the aim of the
study as discussed with the participants. The struc-
tured interview did not detect this increased activity,
which we feel speaks in favour of its validity.
In a previous study of 11 patients modaﬁnil im-
proved excessive daytime sleepiness in MD,
measured with the Multiple Sleep Latency Test and
the Epworth Sleepiness Scale [2]. Possible effects
on spontaneous activity were not considered.
MacDonald et al. [3], in a double-blind cross-over
placebo-controlled study of 40 patients with a time-
scale identical to ours conﬁrmed the reduction of
somnolence as measured by Epworth and Stanford
Sleepiness Scales. They also found modaﬁnil-induced
decreased fatigue-inertia, and increased vigor-activ-
ity, as measured by the Proﬁle of Mood States. The
latter ﬁndings might predict improved observed
activity, but the study did not include this issue and
our study did not demonstrate such effect. Using the
RAND-36 they also observed enhanced measures of
energy and perception of health, but no changes in
the other items of the test; the former effects were
not conﬁrmed in our study. Talbot et al. [4] per-
formed a similar double-blind cross-over study of 19
patients selected for hypersomnolence (ESS 10 or
more points), using the ESS, a Modiﬁed Maintenance
of Wakefulness test (MWT), a steering simulator, the
Short Form 36 and an ‘‘activity diary’’ as measures.
They found a reduction of sleepiness, especially in
the MWT, less convincingly in the ESS. The other
tests did not show signiﬁcant changes. Data from the
activity diaries are not given.
It is apparent that the symptoms referred to as
inertia, reduced initiative, inactivity or apathy are
hard to deﬁne and even harder to measure. Recently,
van der Werf et al. inferred that the lack of correlation
between fatigue scores and sleepiness in MD suggests
that different pathophysiological mechanisms under-
lie these clinical manifestations [7]). We believe that
our ﬁndings point in the same direction.
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